Clinical Trial Update: Antithymocyte Globulin Compared With Supportive Care in Treating Patients With Myelodysplastic Syndrome [Phase 2]

View source ↗

Summary

Phase 2 trial comparing antithymocyte globulin to supportive care in myelodysplastic syndromes has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Antithymocyte Globulin (anti-thymocyte globulin)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Myelodysplastic Syndromes | Phase 2 | Status: COMPLETED